title: Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barré syndrome.
abstract: Complement-mediated disruption of voltage-gated sodium channels at the nodes of Ranvier acts in the development of acute motor axonal neuropathy. Nafamostat mesilate, a synthetic serine protease inhibitor, used in clinical practice for more than 20 years, has anti-complement activity. Acute motor axonal neuropathy rabbits obtained by GM1 ganglioside sensitization were or were not given nafamostat mesilate intravenously. Complement deposition and sodium channel disruption in the spinal anterior roots were significantly less frequent in the treated rabbits than in the controls. Nafamostat mesilate inhibited complement deposition and prevented sodium channel disruption. This provided the rationale for a clinical trial.
authors.affiliation: Department of Neurology, Dokkyo Medical University, Kitakobayashi 880, Mibu, Shimotsuga, Tochigi 321-0293, Japan.
authors.forename: Vongsavanh
authors.initials: V
authors.lastname: Phongsisay
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Susuki
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Matsuno
authors.forename: Takuyu
authors.initials: T
authors.lastname: Yamahashi
authors.forename: Saori
authors.initials: S
authors.lastname: Okamoto
authors.forename: Kei
authors.initials: K
authors.lastname: Funakoshi
authors.forename: Koichi
authors.initials: K
authors.lastname: Hirata
authors.forename: Motoo
authors.initials: M
authors.lastname: Shinoda
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Yuki
mesh_terms: D000818:Animals; D001550:Benzamidines; D003176:Complement C3 / Q000378:metabolism; D051056:Complement Inactivating Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D006146:Guanidines / Q000494:pharmacology* / Q000627:therapeutic use; D020275:Guillain-Barre Syndrome / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D015918:Infusion Pumps, Implantable; D011817:Rabbits; D011897:Random Allocation; D011901:Ranvier's Nodes / Q000187:drug effects* / Q000378:metabolism; D015222:Sodium Channels / Q000378:metabolism*
chemical_list: D001550:Benzamidines; D003176:Complement C3; D051056:Complement Inactivating Agents; D006146:Guanidines; D015222:Sodium Channels; C032855:nafamostat